Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse.

Although many patients have been found to have very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, none have been documented with long-chain acyl-CoA dehydrogenase (LCAD) deficiency. In order to understand the metabolic pathogenesis of long-chain fatty acid oxidation disorders, we generated mice with VLCAD deficiency (VLCAD(-/-)) and compared their pathologic and biochemical phenotypes of mice with LCAD deficiency (LCAD(-/-)) and wild-type mice. VLCAD(-/-) mice had milder fatty change in liver and heart. Dehydrogenation of various acyl-CoA substrates by liver, heart and skeletal muscle mitochondria differed among the three genotypes. The results for liver were most informative as VLCAD(-/-) mice had a reduction in activity toward palmitoyl-CoA and oleoyl-CoA (58 and 64% of wild-type, respectively), whereas LCAD(-/-) mice showed a more profoundly reduced activity toward these substrates (35 and 32% of wild-type, respectively), with a significant reduction of activity toward the branched chain substrate 2,6-dimethylheptanoyl-CoA. C(16) and C(18) acylcarnitines were elevated in bile, blood and serum of fasted VLCAD(-/-) mice, whereas abnormally elevated C(12) and C(14) acylcarnitines were prominent in LCAD(-/-) mice. Progeny with the combined LCAD(+/+)//VLCAD(+/-) genotype were over-represented in offspring from sires and dams heterozygous for both LCAD and VLCAD mutations. In contrast, no live mice with a compound LCAD(-/-)//VLCAD(-/-) genotype were detected.

[1]  J. Vockley,et al.  Mammalian branched-chain acyl-CoA dehydrogenases: molecular cloning and characterization of recombinant enzymes. , 2000, Methods in enzymology.

[2]  馨 伊在井 Novel fatty acid β-oxidation enzymes in rat liver mitochondria : purification and properties of very-long-chain acyl-coenzyme A dehydrogenase , 1992 .

[3]  L. D. Schroeder,et al.  Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. , 1999, American journal of human genetics.

[4]  D. Hale,et al.  Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K Tanaka,et al.  Purification and characterization of short-chain, medium-chain, and long-chain acyl-CoA dehydrogenases from rat liver mitochondria. Isolation of the holo- and apoenzymes and conversion of the apoenzyme to the holoenzyme. , 1985, The Journal of biological chemistry.

[6]  William,et al.  Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. , 1995, The Journal of clinical investigation.

[7]  D. Kurtz,et al.  Abnormal nonshivering thermogenesis in mice with inherited defects of fatty acid oxidation. , 1998, The Journal of clinical investigation.

[8]  Piero Rinaldo,et al.  Ethylmalonic/Adipic Aciduria: Effects of Oral Medium-Chain Triglycerides, Carnitine, and Glycine on Urinary Excretion of Organic Acids, Acylcarnitines, and Acylglycines , 1991, Pediatric Research.

[9]  T Hashimoto,et al.  Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. , 1992, The Journal of biological chemistry.

[10]  T. Hashimoto,et al.  Identification of Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency in Three Patients Previously Diagnosed with Long-Chain Acyl-CoA Dehydrogenase Deficiency , 1993, Pediatric Research.

[11]  M G Blitzer,et al.  Biochemical diagnosis of fatty acid oxidation disorders by metabolite analysis of postmortem liver. , 1994, Human pathology.

[12]  S. Denis,et al.  2,6-Dimethylheptanoyl-CoA is a specific substrate for long-chain acyl-CoA dehydrogenase (LCAD): evidence for a major role of LCAD in branched-chain fatty acid oxidation. , 1998, Biochimica et biophysica acta.

[13]  K. Kristiansen,et al.  Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. , 1996, Human molecular genetics.

[14]  P. Divry,et al.  Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. , 1998, Clinica chimica acta; international journal of clinical chemistry.

[15]  D. Millington,et al.  Application of fast atom bombardment with tandem mass spectrometry and liquid chromatography/mass spectrometry to the analysis of acylcarnitines in human urine, blood, and tissue. , 1989, Analytical biochemistry.

[16]  T. Hashimoto,et al.  Mutation analysis of very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: identification and characterization of mutant VLCAD cDNAs from four patients. , 1996, American journal of human genetics.

[17]  P. A. Wood,et al.  Chromosomal locations of the mouse fatty acid oxidation genes Cpt1a, Cpt1b, Cpt2, Acadvl, and metabolically related Crat gene , 1998, Mammalian Genome.

[18]  T. Aoyama,et al.  Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients. , 1995, American journal of human genetics.

[19]  J B Lowe,et al.  Expression of rat intestinal fatty acid-binding protein in Escherichia coli. Purification and comparison of ligand binding characteristics with that of Escherichia coli-derived rat liver fatty acid-binding protein. , 1987, The Journal of biological chemistry.

[20]  M. Bennett,et al.  Inborn Errors of Mitochondrial Fatty Acid Oxidation , 2000, Critical reviews in clinical laboratory sciences.

[21]  F. Taroni,et al.  Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatocardiomuscular expression. , 1996, American journal of human genetics.

[22]  J. Vockley,et al.  Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. , 2000, Molecular genetics and metabolism.

[23]  A. Mathur,et al.  Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. , 1999, Circulation.

[24]  F. Frerman,et al.  Fluorometric assay of acyl-CoA dehydrogenases in normal and mutant human fibroblasts. , 1985, Biochemical medicine.

[25]  S. Pande Carnitine-acylcarnitine translocase deficiency. , 1999, The American journal of the medical sciences.

[26]  D. Kurtz,et al.  Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Vockley,et al.  Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial beta-oxidation of unsaturated fatty acids. , 2000, Biochimica et biophysica acta.

[28]  P. A. Wood,et al.  Short-Chain Acyl-Coenzyme A Dehydrogenase Activity, Antigen, and Biosynthesis Are Absent in the BALB/cByJ Mouse , 1992, Pediatric Research.